Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Data Lacking On Proton Therapy Vs. Traditional Radiation For Cancer - AHRQ

This article was originally published in The Gray Sheet

Executive Summary

Particle beam radiation - also known as proton therapy - is a "promising" cancer treatment, but potential advantages over alternative radiation therapies remain unproven due to a lack of long-term comparative studies, according to a Sept. 14 Agency for Healthcare Research and Quality technical brief

You may also be interested in...



Evidence Lacking On Proton Therapy For Non-Small-Cell Lung Cancer – BCBS

Blue Cross Blue Shield’s Technology Evaluation Center found there is insufficient evidence that proton beam therapy improves health outcomes for patients with non-small-cell lung cancer.

Evidence Lacking On Proton Therapy For Non-Small-Cell Lung Cancer – BCBS

Blue Cross Blue Shield’s Technology Evaluation Center found there is insufficient evidence that proton beam therapy improves health outcomes for patients with non-small-cell lung cancer.

New Philadelphia Proton Therapy Center Promises Heavy Research Focus

Protons will one day overtake photons as the dominant cancer radiation tool, and research conducted at the new Roberts Proton Therapy Center in Philadelphia will help accelerate the technology's adoption, contends Zelig Tochner, medical director of the facility

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel